Patrick Daly

DocwireNews

Venetoclax is approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when combined with obinutuzumab as a first-line therapy or with rituximab in relapsed or refractory patients. Researchers, led by Anna Teschemaker, analyzed real-world data on treatment patterns in the United States for venetoclax plus obinutuzumab or rituximab. Their findings were presented at the <a href="https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/" target="_blank" rel="noopener">European Hematology Association 2023 Hybrid Congress</a>.Based on retrospective cohort analysis, the researchers found median duration of treatment (DoT) was approximately 12 months for venetoclax plus obinutuzumab and 24 months for venetoclax plus rituximab, both of which were consistent with approved first-line and relapsed or refractory regimens. However, the authors noted a high number of patients did not maintain the fixed-dosing schedule.<h3>Fixed Venetoclax Dosing Schedule May Hamper Treatment</h3>The final analysis included 115 patients in the first-line venetoclax plus obinutuzumab group (mean age, 62.3 years; 73.3% male) and 133 in the relapsed or refractory venetoclax plus rituximab group (mean age, 64.2 years; 73.8% male). Authors noted 48.3% of relapsed or refractory patients had received prior targeted therapies.The DoT was defined as the time from the start of the treatment regimen until either treatment discontinuation or end of follow-up. Investigators used Kaplan-Meier models to estimate the odds of remaining on treatment for both groups.The venetoclax plus obinutuzumab group had a median follow-up of 11.4 months, a median DoT of 12.4 months (95% CI, 11.5-13.4), and a probability of remaining on treatment at month 12, 18, and 24 of 56.4%, 20.2%, and 5.1%, respectively. In 55 (47.8%) first-line patients with 12 or more months of follow-up, 9.1% had fixed-duration treatment cycles and 38.2% discontinued early, with a median DoT of 4.6 months.Comparatively, the venetoclax plus rituximab group had a median follow-up of 15.5 months, a median DoT of 24.5 months (95% CI, 13.4-25.2), and a probability of remaining on treatment at month 24, 30, and 36 of 53.8%, 19.0%, and 19.0%, respectively. Among 39 (29.3%) relapsed or refractory patients with 24 or more months of follow-up, 5.1% had fixed cycles and 46.2% discontinued early, with a median DoT of 7.1 months.Overall, the authors suggested &ldquo;this study provides evidence that a [venetoclax]-based approach may not be suitable for all patients with CLL/SLL. Future studies should include additional follow-up with a larger sample, reasons for treatment discontinuation, and patient molecular genetic profile.&rdquo;View More <a href="https://docwirenews.com/category/eha-2023">Highlights from the EHA 2023 Hybrid Congress</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Real-world Treatment Durations of Venetoclax in CLL, SLL

EHA 2023

Researchers found real-world venetoclax durations were in line with approved CLL treatment regimens, but many patients failed the venetoclax fixed-dosing schedule. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe